Literature DB >> 27559192

Sugammadex.

Dennis J Cada, Terri L Levien, Danial E Baker.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The July 2016 monograph topics are pimavanserin, venetoclax, defibrotide, lifitegrast ophthalmic solution 5%, and atezolizumab. The Safety MUE is on pimavanserin.

Entities:  

Year:  2016        PMID： 27559192      PMCID： PMC4981107          DOI： 10.1310/hpj5107-585

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  34 in total

1.  Sugammadex: a revolutionary approach to neuromuscular antagonism.

Authors:  Aaron F Kopman
Journal:  Anesthesiology       Date:  2006-04       Impact factor: 7.892

2.  Dialysability of sugammadex and its complex with rocuronium in intensive care patients with severe renal impairment.

Authors:  G Cammu; B Van Vlem; M van den Heuvel; L Stet; R el Galta; S Eloot; I Demeyer
Journal:  Br J Anaesth       Date:  2012-06-24       Impact factor: 9.166

3.  Sugammadex is cleared rapidly and primarily unchanged via renal excretion.

Authors:  Pierre Peeters; Paul Passier; Jean Smeets; Alex Zwiers; Marcel de Zwart; Saskia van de Wetering-Krebbers; Marlou van Iersel; Sjoerd van Marle; Diels van den Dobbelsteen
Journal:  Biopharm Drug Dispos       Date:  2011-03-01       Impact factor: 1.627

4.  First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide.

Authors:  Francois Gijsenbergh; Steven Ramael; Natalie Houwing; Thijs van Iersel
Journal:  Anesthesiology       Date:  2005-10       Impact factor: 7.892

5.  Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent.

Authors:  Koen Suy; Karl Morias; Guy Cammu; Pol Hans; Wilbert G F van Duijnhoven; Marten Heeringa; Ignace Demeyer
Journal:  Anesthesiology       Date:  2007-02       Impact factor: 7.892

6.  Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine.

Authors:  Ozlem Sacan; Paul F White; Burcu Tufanogullari; Kevin Klein
Journal:  Anesth Analg       Date:  2007-03       Impact factor: 5.108

7.  A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery.

Authors:  G Geldner; M Niskanen; P Laurila; V Mizikov; M Hübler; G Beck; H Rietbergen; E Nicolayenko
Journal:  Anaesthesia       Date:  2012-06-14       Impact factor: 6.955

8.  Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.

Authors:  Karin S Khuenl-Brady; Magnus Wattwil; Bernard F Vanacker; José I Lora-Tamayo; Henk Rietbergen; José A Alvarez-Gómez
Journal:  Anesth Analg       Date:  2009-08-27       Impact factor: 5.108

9.  Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers.

Authors:  G Cammu; P J De Kam; I Demeyer; M Decoopman; P A M Peeters; J M W Smeets; L Foubert
Journal:  Br J Anaesth       Date:  2008-01-31       Impact factor: 9.166

10.  Simulation of the reversal of neuromuscular block by sequestration of the free molecules of the muscle relaxant.

Authors:  Vladimir Nigrovic; Shashi B Bhatt; Anton Amann
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-09-21       Impact factor: 2.410
View more
  4 in total

Review 1.  Pharmacokinetics in sepsis.

Authors:  M Charlton; J P Thompson
Journal:  BJA Educ       Date:  2018-11-09

2.  [Pituitary tumor resection in a patient with SARS-CoV-2 (COVID-19) infection. A case report and suggested airway management guidelines].

Authors:  Christiano Dos Santos E Santos; Luiz M da Costa Lima Filho; Cristiane A Tuma Santos; James S Neill; Henrique F Vale; Lakshmi N Kurnutala
Journal:  Braz J Anesthesiol       Date:  2020-06-09

3.  A Meta-Analysis on the Effect of Dexamethasone on the Sugammadex Reversal of Rocuronium-Induced Neuromuscular Block.

Authors:  Chang-Hoon Koo; Jin-Young Hwang; Seong-Won Min; Jung-Hee Ryu
Journal:  J Clin Med       Date:  2020-04-24       Impact factor: 4.241

Review 4.  Cyclodextrin-based Pickering emulsions: functional properties and drug delivery applications.

Authors:  Mario Jug; Bo Kyeong Yoon; Joshua A Jackman
Journal:  J Incl Phenom Macrocycl Chem       Date:  2021-08-03       Impact factor: 1.633
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.